Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...
Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...
The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.
which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...
Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...
The Food and Drug Administration approves biosimilars ... low count of white blood cells named neutrophils) in cancer patients, faced biosimilar competition in Europe as early as 2008, seven ...
The Hill on MSN13d
Biden administration picks 15 more drugs for Medicare negotiationThe drugs treat conditions such as diabetes and cancer, and seniors across the country rely on ... including those that have ...
New Delhi, Dec 2 () Biotechnology major Biocon and drug firm Mylan NV on ... US and the second FDA-approved biosimilar through this collaboration to support cancer patients, the statement said.
Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback